Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Pharmaron Beijing

SEHK:3759
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3759
SEHK
CN¥46B
Market Cap
  1. Home
  2. HK
  3. Pharmaceuticals & Biotech
Company description

Pharmaron Beijing Co., Ltd. provides research and development services to the life sciences industry. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Pharmaron Beijing has significant price volatility in the past 3 months.
3759 Share Price and Events
7 Day Returns
13.5%
SEHK:3759
9.5%
HK Life Sciences
0.2%
HK Market
1 Year Returns
-
SEHK:3759
26.8%
HK Life Sciences
-22%
HK Market
3759 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pharmaron Beijing (3759) 13.5% -4% 26.2% - - -
HK Life Sciences 9.5% -10.2% 1.4% 26.8% 107.5% 53.6%
HK Market 0.2% -10.8% -16.5% -22% -13.4% -28.8%
1 Year Return vs Industry and Market
  • No trading data on 3759.
  • No trading data on 3759.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Pharmaron Beijing undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Pharmaron Beijing to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Pharmaron Beijing.

SEHK:3759 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year HK Government Bond Rate 1.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SEHK:3759
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year HK Govt Bond Rate 1.6%
Equity Risk Premium S&P Global 6.3%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.03 (1 + (1- 25%) (2.28%))
1.032
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.55% + (1.032 * 6.33%)
8.08%

Discounted Cash Flow Calculation for SEHK:3759 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Pharmaron Beijing is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SEHK:3759 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8.08%)
2020 -227.74 Analyst x1 -210.71
2021 67.24 Analyst x1 57.56
2022 1,092.06 Analyst x1 864.92
2023 1,344.76 Analyst x1 985.41
2024 1,530.73 Est @ 13.83% 1,037.80
2025 1,686.04 Est @ 10.15% 1,057.61
2026 1,813.62 Est @ 7.57% 1,052.56
2027 1,918.12 Est @ 5.76% 1,029.96
2028 2,004.40 Est @ 4.5% 995.80
2029 2,076.84 Est @ 3.61% 954.63
Present value of next 10 years cash flows CN¥7,825.00
SEHK:3759 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥2,076.84 × (1 + 1.55%) ÷ (8.08% – 1.55%)
CN¥32,283.48
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥32,283.48 ÷ (1 + 8.08%)10
CN¥14,839.27
SEHK:3759 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥7,825.00 + CN¥14,839.27
CN¥22,664.27
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥22,664.27 / 794.39
CN¥28.53
SEHK:3759 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in SEHK:3759 represents 0.9264x of SZSE:300759
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.9264x
Value per Share
(Listing Adjusted, HKD)
= Value per Share (CNY) x Listing Adjustment Factor
= CN¥ 28.53 x 0.9264
HK$26.43
Value per share (HKD) From above. HK$26.43
Current discount Discount to share price of HK$54.50
= -1 x (HK$54.50 - HK$26.43) / HK$26.43
-106.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Pharmaron Beijing is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pharmaron Beijing's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pharmaron Beijing's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SEHK:3759 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CNY CN¥0.83
SZSE:300759 Share Price ** SZSE (2020-04-03) in CNY CN¥58.83
Hong Kong Life Sciences Industry PE Ratio Median Figure of 6 Publicly-Listed Life Sciences Companies 36.39x
Hong Kong Market PE Ratio Median Figure of 1,475 Publicly-Listed Companies 9.06x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pharmaron Beijing.

SEHK:3759 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SZSE:300759 Share Price ÷ EPS (both in CNY)

= 58.83 ÷ 0.83

71.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmaron Beijing is overvalued based on earnings compared to the HK Life Sciences industry average.
  • Pharmaron Beijing is overvalued based on earnings compared to the Hong Kong market.
Price based on expected Growth
Does Pharmaron Beijing's expected growth come at a high price?
Raw Data
SEHK:3759 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 71.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
25.3%per year
Asia Life Sciences Industry PEG Ratio Median Figure of 20 Publicly-Listed Life Sciences Companies 1.81x
Hong Kong Market PEG Ratio Median Figure of 487 Publicly-Listed Companies 0.64x

*Line of best fit is calculated by linear regression .

SEHK:3759 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 71.02x ÷ 25.3%

2.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmaron Beijing is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Pharmaron Beijing's assets?
Raw Data
SEHK:3759 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CNY CN¥9.78
SZSE:300759 Share Price * SZSE (2020-04-03) in CNY CN¥58.83
Hong Kong Life Sciences Industry PB Ratio Median Figure of 7 Publicly-Listed Life Sciences Companies 4.63x
Hong Kong Market PB Ratio Median Figure of 2,250 Publicly-Listed Companies 0.71x
SEHK:3759 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SZSE:300759 Share Price ÷ Book Value per Share (both in CNY)

= 58.83 ÷ 9.78

6.02x

* Primary Listing of Pharmaron Beijing.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmaron Beijing is overvalued based on assets compared to the HK Life Sciences industry average.
X
Value checks
We assess Pharmaron Beijing's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Pharmaron Beijing has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pharmaron Beijing expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pharmaron Beijing expected to grow at an attractive rate?
  • Pharmaron Beijing's earnings growth is expected to exceed the low risk savings rate of 1.6%.
Growth vs Market Checks
  • Pharmaron Beijing's earnings growth is expected to exceed the Hong Kong market average.
  • Pharmaron Beijing's revenue growth is expected to exceed the Hong Kong market average.
Annual Growth Rates Comparison
Raw Data
SEHK:3759 Future Growth Rates Data Sources
Data Point Source Value (per year)
SEHK:3759 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 25.3%
SEHK:3759 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 21%
Asia Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 28.3%
Asia Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 22.3%
Hong Kong Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Hong Kong Market Revenue Growth Rate Market Cap Weighted Average 9.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SEHK:3759 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SEHK:3759 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 8,977 1,600 1
2022-12-31 7,523 1,297 1,309 2
2021-12-31 6,001 1,016 1,017 2
2020-12-31 4,762 774 744 2
2020-04-04
SEHK:3759 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-12-31 3,757 939 547
2019-09-30 3,499 784 443
2019-06-30 3,274 832 384
2019-03-31 3,089 787 353
2018-12-31 2,908 791 333
2018-09-30 2,713 692 300
2017-12-31 2,294 552 231

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pharmaron Beijing's earnings are expected to grow significantly at over 20% yearly.
  • Pharmaron Beijing's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SEHK:3759 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Pharmaron Beijing Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:3759 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.42 2.42 2.42 1.00
2022-12-31 1.81 1.92 1.70 2.00
2021-12-31 1.23 1.51 0.89 3.00
2020-12-31 1.03 1.12 0.94 2.00
2020-04-04
SEHK:3759 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-12-31 0.83
2019-09-30 0.69
2019-06-30 0.60
2019-03-31 0.58
2018-12-31 0.56
2018-09-30 0.51
2017-12-31 0.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Pharmaron Beijing is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Pharmaron Beijing's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pharmaron Beijing has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pharmaron Beijing performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pharmaron Beijing's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pharmaron Beijing has delivered over 20% year on year earnings growth in the past 5 years.
  • Pharmaron Beijing's 1-year earnings growth exceeds its 5-year average (64.3% vs 32.5%)
  • Pharmaron Beijing's earnings growth has exceeded the HK Life Sciences industry average in the past year (64.3% vs 62.3%).
Earnings and Revenue History
Pharmaron Beijing's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pharmaron Beijing Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:3759 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3,757.16 547.19 574.08 62.87
2019-09-30 3,499.11 443.07 543.17 51.06
2019-06-30 3,274.06 384.08 505.22 43.74
2019-03-31 3,089.29 352.80 494.24 33.83
2018-12-31 2,908.12 333.04 461.24 31.61
2018-09-30 2,713.15 300.07 685.78 46.14
2017-12-31 2,294.12 230.86 373.78 22.61
2016-12-31 1,634.24 176.91 280.24
2015-12-31 1,128.04 73.85 221.00
2014-12-31 790.44 21.00 155.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Pharmaron Beijing has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Pharmaron Beijing used its assets less efficiently than the HK Life Sciences industry average last year based on Return on Assets.
  • Pharmaron Beijing's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Pharmaron Beijing's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pharmaron Beijing has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pharmaron Beijing's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pharmaron Beijing's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pharmaron Beijing is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pharmaron Beijing's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pharmaron Beijing's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pharmaron Beijing Company Filings, last reported 3 months ago.

SEHK:3759 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 7,838.02 821.52 4,643.30
2019-09-30 3,070.88 1,493.72 460.19
2019-06-30 2,916.26 1,297.01 464.54
2019-03-31 2,833.22 1,545.32 825.98
2018-12-31 2,325.64 1,373.76 321.12
2018-09-30 2,239.99 1,001.75
2017-12-31 2,010.29 1,243.33 305.50
2016-12-31 1,763.42 564.24 470.21
2015-12-31 168.43 184.68 87.05
2014-12-31 258.25 211.90 41.02
  • Pharmaron Beijing's level of debt (10.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (82.1% vs 10.5% today).
  • Debt is well covered by operating cash flow (114.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 9.1x coverage).
X
Financial health checks
We assess Pharmaron Beijing's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pharmaron Beijing has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pharmaron Beijing's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.25%
Current annual income from Pharmaron Beijing dividends. Estimated to be 0.53% next year.
If you bought HK$2,000 of Pharmaron Beijing shares you are expected to receive HK$5 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Pharmaron Beijing's pays a lower dividend yield than the bottom 25% of dividend payers in Hong Kong (2.6%).
  • Pharmaron Beijing's dividend is below the markets top 25% of dividend payers in Hong Kong (7.27%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SEHK:3759 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Asia Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 0.5%
Hong Kong Market Average Dividend Yield Market Cap Weighted Average of 951 Stocks 4.3%
Hong Kong Minimum Threshold Dividend Yield 10th Percentile 1.3%
Hong Kong Bottom 25% Dividend Yield 25th Percentile 2.6%
Hong Kong Top 25% Dividend Yield 75th Percentile 7.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SEHK:3759 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 0.48 1.00
2022-12-31 0.36 2.00
2021-12-31 0.28 2.00
2020-12-31 0.21 2.00
2020-04-04
SEHK:3759 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2020-03-30 0.150 0.256
2020-02-28 0.150 0.259
2019-04-19 0.110 0.255

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmaron Beijing is not paying a notable dividend for Hong Kong, therefore no need to check if the payments are stable.
  • Pharmaron Beijing is not paying a notable dividend for Hong Kong, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Pharmaron Beijing's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Pharmaron Beijing's dividends as it is not paying a notable one for Hong Kong.
Future Payout to shareholders
  • No need to calculate the sustainability of Pharmaron Beijing's dividends in 3 years as they are not expected to pay a notable one for Hong Kong.
X
Income/ dividend checks
We assess Pharmaron Beijing's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pharmaron Beijing afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pharmaron Beijing has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pharmaron Beijing's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Boliang Lou
CEO Bio

Dr. Boliang Lou, Ph.D serves as Chairman of the Board and Chief Executive Officer at Pharmaron, Inc. Dr. Lou serves as the Chairman, Chief Executive Officer and Manager of Pharmaron Beijing Co., Ltd. Dr. Lou co-founded Pharmaron in 2003. He served as the Director of Research at Advanced SynTech (AST), managed a multi-discipline team working in the area of drug discovery, combinatorial, high throughput medicinal and computational chemistry. At AST, he was responsible for all the collaboration projects with various pharmaceutical, biotech companies and academic institutions around the world. Dr. Lou is an author of over 50 papers, book chapters and presentations, and is an inventor on more than 15 patents and patent applications. He received his M. S. degree (1986) and Ph.D. in organic chemistry (1989) under the supervision of Professor Li-Xin Dai at the Shanghai Institute of Organic Chemistry (SIOC). He did post-doctoral research with Professor Stephen Hanessian at the University of Montreal (1990-1994). Dr. Lou then joined Cytel Corporation as a Staff Scientist in 1994. He began working on combinatorial chemistry after joining Ontogen Corporation in 1996. One year later, he moved to Helios Pharmaceutical (later as Advanced SynTech) as Staff Researcher II and became the Research Section Head of Chemistry in 1998 and the Director of Research in 2002.

CEO Compensation
  • Insufficient data for Boliang to compare compensation growth.
  • Insufficient data for Boliang to establish whether their remuneration is reasonable compared to companies of similar size in Hong Kong.
Management Team

Boliang Lou

TITLE
Chairman

Gilbert Li

TITLE
CFO & Secretary of the Board

Hua Yang

TITLE
Chief Scientific Officer & Deputy Manager

Connie Sun

TITLE
Executive

Katherine Lee

TITLE
Executive

Jane Zhang

TITLE
Executive
Board of Directors

Boliang Lou

TITLE
Chairman

Richard Li

TITLE
Director
AGE
46

Hongbin Zhou

TITLE
Director

Kexin Yang

TITLE
Supervisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (HK$) Value (HK$)
02. Apr 20 Buy J.P. Morgan Asset Management, Inc. Company 30. Mar 20 30. Mar 20 519,600 HK$48.30 HK$25,095,746
01. Apr 20 Sell Wellington Management Group LLP Company 31. Mar 20 31. Mar 20 -266,300 HK$50.54 HK$-13,458,002
01. Apr 20 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 27. Mar 20 27. Mar 20 298,198 HK$48.26 HK$14,391,870
31. Mar 20 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 26. Mar 20 26. Mar 20 -607,879 HK$48.81 HK$-29,671,605
31. Mar 20 Sell JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 26. Mar 20 26. Mar 20 -9,400 HK$48.81 HK$-458,830
31. Mar 20 Buy J.P. Morgan Asset Management, Inc. Company 26. Mar 20 26. Mar 20 50,500 HK$48.81 HK$2,464,991
30. Mar 20 Buy J.P. Morgan Asset Management, Inc. Company 25. Mar 20 25. Mar 20 726,740 HK$46.32 HK$33,664,702
20. Mar 20 Buy J.P. Morgan Asset Management, Inc. Company 17. Mar 20 17. Mar 20 270,840 HK$42.19 HK$11,427,390
17. Mar 20 Sell Wellington Management Group LLP Company 16. Mar 20 16. Mar 20 -286,100 HK$45.90 HK$-13,131,990
28. Feb 20 Sell Wellington Management Group LLP Company 26. Feb 20 26. Feb 20 -38,900 HK$54.46 HK$-2,118,455
24. Feb 20 Sell Wellington Management Group LLP Company 20. Feb 20 20. Feb 20 -1,430,300 HK$55.17 HK$-78,915,370
13. Feb 20 Buy J.P. Morgan Asset Management, Inc. Company 10. Feb 20 10. Feb 20 521,100 HK$56.02 HK$29,190,876
11. Feb 20 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 06. Feb 20 06. Feb 20 -304,200 HK$53.38 HK$-16,238,258
10. Feb 20 Sell Wellington Management Group LLP Company 05. Feb 20 05. Feb 20 -1,550,500 HK$53.33 HK$-82,688,161
06. Feb 20 Sell J.P. Morgan Asset Management, Inc. Company 03. Feb 20 03. Feb 20 -2,023,429 HK$49.86 HK$-100,884,927
03. Feb 20 Buy Wellington Management Group LLP Company 30. Jan 20 30. Jan 20 170,900 HK$49.36 HK$8,435,454
09. Jan 20 Buy J.P. Morgan Asset Management, Inc. Company 06. Jan 20 06. Jan 20 1,176,771 HK$43.06 HK$50,673,521
03. Jan 20 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 30. Dec 19 30. Dec 19 3,075,300 HK$44.57 HK$137,050,747
03. Jan 20 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 30. Dec 19 30. Dec 19 9,000 HK$44.57 HK$401,085
03. Jan 20 Buy J.P. Morgan Asset Management, Inc. Company 30. Dec 19 30. Dec 19 165,100 HK$44.57 HK$7,357,682
02. Jan 20 Sell J.P. Morgan Asset Management, Inc. Company 27. Dec 19 27. Dec 19 -101,199 HK$44.95 HK$-4,548,895
31. Dec 19 Buy Wellington Management Group LLP Company 30. Dec 19 30. Dec 19 132,400 HK$43.90 HK$5,812,890
31. Dec 19 Buy Wellington Management Group LLP Company 27. Dec 19 27. Dec 19 687,700 HK$44.93 HK$30,901,111
24. Dec 19 Buy Wellington Management Group LLP Company 20. Dec 19 20. Dec 19 147,000 HK$44.30 HK$6,512,099
13. Dec 19 Buy Wellington Management Group LLP Company 11. Dec 19 11. Dec 19 214,700 HK$42.70 HK$9,168,549
10. Dec 19 Buy Wellington Management Group LLP Company 06. Dec 19 06. Dec 19 500,900 HK$43.30 HK$21,687,466
04. Dec 19 Buy J.P. Morgan Asset Management, Inc. Company 29. Nov 19 29. Nov 19 4,173,700 HK$40.95 HK$170,925,108
03. Dec 19 Buy Wellington Management Group LLP Company 29. Nov 19 29. Nov 19 1,442,600 HK$40.97 HK$59,100,433
03. Dec 19 Buy Wellington Management Group LLP Company 02. Dec 19 02. Dec 19 863,800 HK$41.36 HK$35,726,770
30. Nov 19 Buy Capital Research and Management Company Company 28. Nov 19 28. Nov 19 15,414,700 HK$41.57 HK$640,747,409
X
Management checks
We assess Pharmaron Beijing's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pharmaron Beijing has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Pharmaron Beijing Co., Ltd. provides research and development services to the life sciences industry. It offers research and development service capabilities range from synthetic; medicinal and analytical chemistry; biology; DMPK; pharmacology; drug safety assessment; radiochemistry and isotopically labelled metabolism; and chemical, pharmaceutical, and clinical development. The company has operations in the People's Republic of China, the United States, and the United Kingdom. Pharmaron Beijing Co., Ltd. was founded in 2004 and is headquartered in Beijing, the People's Republic of China.

Details
Name: Pharmaron Beijing Co., Ltd.
3759
Exchange: SEHK
Founded: 2004
CN¥49,782,174,118
794,387,462
Website: http://www.pharmaron.com
Address: Pharmaron Beijing Co., Ltd.
6 Taihe Road,
BDA,
Beijing,
100176,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SZSE 300759 Domestic Shares Shenzhen Stock Exchange CN CNY 28. Jan 2019
XSEC 300759 Domestic Shares Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect CN CNY 28. Jan 2019
SEHK 3759 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong Ltd. HK HKD 28. Nov 2019
DB 17Q1 Foreign Shares-Foreign Listed Deutsche Boerse AG DE EUR 28. Nov 2019
SZSC 3759 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect HK HKD 28. Nov 2019
Number of employees
Current staff
Staff numbers
7,393
Pharmaron Beijing employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 15:26
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/29
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.